Stifel Reiterates Buy Rating on Iveric Bio (ISEE) as Zimura 'Checks All Efficacy AND Safety Boxes'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CRWD
6. CHKP
7. AMD
8. ON
9. HNGE
10. INSP

Go back to Stifel Reiterates Buy Rating on Iveric Bio (ISEE) as Zimura 'Checks All Efficacy AND Safety Boxes'

Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

September 6, 2022 6:00 AM EDT

- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area -

- Statistically Significant Result with Favorable Safety Profile -

- Post-hoc Analysis of U.S. Patients: 25.5% Reduction (p-value = 0.0037) Using Square Root Transformation; 32.0% Reduction (p-value = 0.0033) Using Observed GA Area -

- Plan to Submit New Drug Application to the FDA by the End of the First Quarter 2023 -

-... More

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2022 8:00 AM EDT

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were approved by the Companys compensation and talent strategy committee pursuant to a... More